Tradestie Institutional Equity Comparison Engine
MXCT vs TMCI โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TMCI Overall Edge
TMCI Captures Institutional Edge (3โ0 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Treace Medical Concepts, Inc. Common Stock (TMCI) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MXCT trades at N/M Forward P/E with -85.5% operating margin (+48.7% YoY revenue) versus TMCI at N/M Forward P/E and -24.4% operating margin (-3.9% YoY). In options structure, MXCT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against TMCI sits in CONSOLIDATION (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
MXCT N/M vs TMCI N/M Fwd P/E
Growth & Margin Winner
TMCI
Op Margin -85.5% vs -24.4% ยท YoY +48.7% vs -3.9%
Momentum & Technical Winner
TMCI
1Y -19.4% vs +58.5% ยท 52W Pos 63% vs 74%
Options & Structure Winner
TMCI
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (100th %ile IV)
MXCT
NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap
$132.2M
1M Return
-4.2%
1Y Return
-19.41%
Forward P/E
N/M
Unified AI Score
41.7 / 100
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
TMCI
NASDAQ
Treace Medical Concepts, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$4.31
-0.92% 1D
Market Cap
$285.2M
1M Return
+0.7%
1Y Return
+58.46%
Forward P/E
N/M
Unified AI Score
42.7 / 100
HOLD
Tech 25.0
Fund 45.0
Flow 67.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MXCT -19.41%
TMCI +58.46%
Spread: +77.87 pp (TMCI Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MXCT Revenue | TMCI Revenue | MXCT Op. Margin | TMCI Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | $40M | -93.7% | -9.0% | TMCI |
| FY2020 | $20M | $60M | -71.6% | 1.5% | TMCI |
| FY2021 | $20M | $90M | -84.3% | -17.5% | TMCI |
| FY2022 | $30M | $140M | -95.2% | -24.6% | TMCI |
| FY2023 | $20M | $190M | -247.7% | -27.5% | TMCI |
| FY2024 | $20M | $210M | -230.5% | -26.6% | TMCI |
| FY2025 | $20M | $210M | -247.6% | -25.5% | TMCI |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MXCT | TMCI | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $132.2M | $285.2M | Larger Scale | TMCI |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +48.7% | -3.9% | Higher Growth | MXCT |
| Operating Margin (TTM) Profitability | -85.5% | -24.4% | Higher Margin | TMCI |
| Net Profit Margin Profitability | -81.4% | -27.4% | Higher Margin | TMCI |
| Return on Equity (ROE) Capital Efficiency | -16.9% | -74.0% | Higher ROE | MXCT |
| 52-Week Range Position Momentum | 63% ($1โ$2) | 74% ($1โ$5) | Stronger Trend | TMCI |
| Beta / 30D Volatility Risk Regime | 1.19ฮฒ ยท 96% Vol | 2.03ฮฒ ยท 110% Vol | Lower Realized Risk | MXCT |
| Unified Institutional Score Composite Signal | 41.7 / 100 (SELL) | 42.7 / 100 (HOLD) | Higher Composite | TMCI |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MXCT vs TMCI Buy Guide
MXCT
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
TMCI
CONSOLIDATION
106d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MXCT nor TMCI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.